EULAR 2025: SLE & LN Breakthroughs

Join us for an in-depth exploration of the most impactful developments presented at the EULAR 2025 Congress, focusing specifically on Systemic Lupus Erythematosus and Lupus Nephritis. We break down the key takeaways, including:- New insights into hydroxychloroquine monitoring and glucocorticoid tapering guidance - "LAMDA," a novel scoring system for lupus arthritis - Breakthroughs in LN treatment, including the REGENCY trial for obinutuzumab and combinations with existing therapies. - Updated perspectives on belimumab and anifrolumab, exciting novel therapies in development, and the future of cellular therapies for severe lupus.Disclaimer: During Lupus Academy podcast episodes, participants may refer to off-label use of medicines for patients with lupus. Lupus Academy does not make anyrecommendations about using a medicine outside the terms of its approved license for use.